One common attribute of herpesviruses is the ability to establish latent, life-long infections. The role of virus-virus interaction in viral reactivation between or among herpesviruses has not been studied. Preliminary experiments in our laboratory had indicated that infection of Epstein-Barr virus (EBV) genome-positive human lymphoid cell lines with human herpesvirus 6 (HHV-6) results in EBV reactivation in these cells. To further our knowledge of this complex phenomenon, we investigated the effect of HHV-6 infection on expression of the viral lytic cycle proteins of EBV. Our results indicate that HHV-6 upregulates, by up to 10-fold, expression of the immediate-early Zebra antigen and the diffuse and restricted (85 kDa) early antigens (EA-D and EA-R, respectively) in both EBV producer and nonproducer cell lines (i.e., P3HR1, Akata, and Raji). Maximal EA-D induction was observed at 72 h post-HHV-6 infection. Furthermore, expression of late EBV gene products, namely, the viral capsid antigen (125 kDa) and viral membrane glycoprotein gp350, was also increased in EBV producer cells (P3HR1 and Akata) following infection by HHV-6. By using dual-color membrane immunofluorescence, it was found that most of the cells expressing viral membrane glycoprotein gp350 were also positive for HHV-6 antigens, suggesting a direct effect of HHV-6 replication on induction of the EBV replicative cycle. No expression of late EBV antigens was observed in Raji cells following infection by HHV-6, implying a lack of functional complementation between the deleted form of EBV found in Raji cells and the superinfecting HHV-6. The susceptibility of the cell lines to infection by HHV-6 correlated with increased expression of various EBV proteins in that B95-8 cells, which are not susceptible to HHV-6 infection, did not show an increase in expression of EBV antigens following treatment with HHV-6. Moreover, UV lightirradiated or heat-inactivated HHV-6 had no upregulating effect on the Zebra antigen or EA-D in Raji cells, indicating that infectious virus is required for the observed effects of HHV-6 on these EBV products. These results show that HHV-6, another lymphotropic human herpesvirus, can activate EBV replication and may thus contribute to the pathogenesis of EBV-associated diseases.
Herpesviruses are ubiquitous pathogens found throughout the animal kingdom. Infection by human herpesviruses usually occurs during childhood and generally runs a benign course. Occasionally, more serious complications are observed. Some of these herpesviruses are known by their marked lymphotropism, as well as their association with immunopathological disorders. For example, primary infection of young adults by the Epstein-Barr virus (EBV) can lead to a self-limiting lymphoproliferative disease known as infectious mononucleosis (24, 25) . Furthermore, the presence of EBV genomes has been documented in cells of anaplastic nasopharyngeal carcinoma (55, 73) , African Burkitt's lymphoma (27, 42) , and non-Hodgkin's lymphomas in immunosuppressed individuals (20, 21) . Transmission of EBV occurs almost exclusively through saliva. Infectious virus can be recovered from the oropharynx in the majority of infectious mononucleosis patients and from healthy seropositive individuals (17) . EBV can infect, in vivo, both the lymphoid and epithelial tissues of the nasopharynx. In vitro, EBV immortalizes human and primate B lymphocytes. These lymphoblastoid cell lines (LCL) produce little, if any, infectious virus. The viral genome is maintained as an episome, and its expression is limited to a small number of nuclear and latent membrane proteins (12) .
Another lymphotropic human herpesvirus gaining increasing medical attention is human herpesvirus 6 (HHV-6). It was first isolated in 1986 from peripheral blood leukocyte cultures * Corresponding author.
of patients with lymphoproliferative disorders and AIDS (58) . HHV-6 has been identified as the causative agent of exanthem subitum (62, 67) . HHV-6 has also been associated with heterophile-negative infectious mononucleosis (60) , meningoencephalitis (31) , hepatitis (4, 14) , fatal hemophagocytic syndrome (29) , and interstitial pneumonitis (8) . Like that of EBV, transmission of HHV-6 is thought to occur through saliva, and primary infections occur within the first 3 years of life (6, 22, 50) . HHV-6 can infect many cell types, most of which are constituents of the immune system (2, 40, 47) . Interestingly, human B cells appear to be particularly susceptible to HHV-6 infection in vitro only if they have been previously infected with EBV (1).
A common property of herpesviruses is establishment of latency following primary infection. Consequently, these viruses have the potential to reactivate and cause serious secondary infections, especially in immunocompromised hosts. The factors which cause these viruses to reactivate are not fully known. It has been documented that in immunocompromised hosts, EBV and HHV-6 are reactivated and can be recovered from these patients at a higher frequency (3, 21, 35, 68, 69) . EBV reactivation in such hosts leads to increased susceptibility to development of EBV genome-positive, non-Hodgkin-type (B-cell) lymphomas (20, 21) . Indeed, experiments using the severe combined immunodeficient mouse model and inoculation with peripheral blood leukocytes from EBV-seropositive donors have also shown a correlation between EBV reactivation and the development of such lymphomas (49) . Further-EBV REACTIVATION BY HHV-6 6769 more, there is evidence that EBV reactivation can be associated with severe chronic diseases (59) .
Factors that influence viral reactivation include viruses themselves. The model which has been best studied is that of reactivation of human immunodeficiency virus type 1 (HIV-1) by DNA viruses (16, 28, 45, 48, 51) . These DNA viruses, which include herpesviruses, activate HIV replication through transactivation of the long terminal repeat of HIV. Furthermore, some herpesviruses can also induce the synthesis of cytokines, such as tumor necrosis factor alpha and interleukin-6, which are known to reactivate HIV (15, 19) . Consequently, in HIV-infected individuals, reactivation of latent herpesviruses can lead to increased expression of HIV, which in turn may accentuate the downfall of an already impaired immune system.
Viral cofactors in the evolution of EBV-related lymphomas have not been elucidated. The detection of HHV-6 genomic sequences in some B-cell neoplasias (1, 32, 63) and the potential of an HHV-6 genomic segment in transforming rodent cells (57) Virus production. HHV-6 (GS strain) was propagatcd in HSB-2 cells as described previously (15) . Briefly, HHV-6-infected HSB-2 cells were mixed with uninfected cells at a ratio of 1:10. When 75Cc of the cells showed cytopathic effccts (CPE), as determined by light microscopy, cell-free culturc fluid was harvested and filtered through a 0.45-[Lm-pore-size filter and the virus was pelleted by centrifugation (25,000 x g) for 90 min at 4°C. The virus pellct was suspended in RPMI 1640 and frozen at -X85C until used. The HHV-6 titer, expressed as the 50% tissue culture infective dose, was determined by scoring the number of HSB-2 cclls cxhibiting CPE.
The virus stock used had a titer of 105 50%Sf tissue culture infective doses/ml. The mock-infccted control was preparcd from uninfected HSB-2 culture supernatant as described above.
Infection of cell lines. Cells (2 x 10" to 3 x 10") were pelleted and either infected with HHV-6 (1(4 50% tissue culture infective doses/ml for 10" cells), mock infectcd, or treated with UV-irradiated HHV-6 (1 h) or hcat-inactivated HHV-6 (56°C, 1 h) for 2 h at 37°C and subsequcntly suspended in 10 ml of culture medium. The experimental conditions for virus inactivation were the same as in our earlier studies and were found to inactivate over 99% of viral infectivity without, however, affecting the ability of viral particles to modulate cytokine gene expression when infectivity was not required ( 15, 19) . Cells were harvested at different times, washed with phosphate-buffered saline (PBS; pH 7.4), and processed for fluorescence microscopy, Western blotting (immunoblotting), or Southern blotting.
Immunofluorescence assays. PBS-washed cells were processed for immunofluorescence by acetone fixation at -20(C. Following I h of incubation with the primary antibody, slides were washed and the fluorescein-conjugated goat anti-mouse immunoglobulin G (IgG) secondary antibody (Ortho Diagnostics, Raritan, N.J.) was added for I h. Slides were then washed with PBS, mounted, and examined with an Axioskop fluorescence microscope (Zeiss). The percentage of positive cells was calculated after at least 200 cells had been counted. Statistical significance was determined by using a X-test. A P value of <0.05 was considered significant.
Cell surface expression of viral antigens was evaluated by flow cytometric analysis. Briefly, cells were washed with PBS, incubated with specific MAb preparations for 1 h at 4°C, and washed with PBS. Fluorescein-conjugated goat anti-mouse IgG was then added, and the mixture was incubated for I h at 4°C. Cells were then washed in PBS, fixed with i0c paraformaldehyde in PBS, and analyzed with a FACScan apparatus (Becton-Dickinson). For dual-color membrane immunofluorescence, cells were incubated with both 2L10-FITC and plE8-RITC for I h at 4°C and then washed with PBS. Cells were examined by fluorescence microscopy.
Western blotting. Cells were lysed in sodium dodecyl sulfate (SDS) sample buffer, sonicated, boiled, and frozen until used. An amount approximating 3 x 10' cells was loaded per lane of an 8% denaturing SDS-polyacrylamide gel as described by Laemmli (38) . Proteins were transferred onto nitrocellulose membranes and processed for Western blotting (64) . Immunoreactive proteins were visualized by chemiluminescence with the ECL detection kit (Amersham).
Southern blotting. Genomic DNAs were extracted from HHV-6-infected and mock-infected cells after 72 h of culture.
Five micrograms of DNA was digested with Hin1dIII and then electrophoresed through a 0.8% agarose gel. DNA was transferred onto nylon membranes and cross-linked with UV light. Membranes were blocked before being hybridized overnight with 32P-labelled pZVH14 as described previously (33) . Mem 
RESULTS
Susceptibility of cell lines to HHV-6 infection. To evaluate whether HHV-6 can affect the expression of EBV antigens in B cells, it was first necessary to determine the susceptibility of different B-cell lines to HHV-6. All of the B-cell lines tested, with the exception of B95-8 cells, were found to be susceptible to infection with HHV-6. P3HR1, Akata, and Raji cells and LCL were easily infected and showed the characteristic CPE of HHV-6-infected cells. The susceptibility of these cell lines to HHV-6 infection was also monitored by immunofluorescence and Southern blotting. HHV-6 antigen expression in these various cell lines was detected by conventional immunofluorescence assays. The 41-kDa early component of HHV-6, which reacts with the D12 MAb, was detected in all of the infected cell lines, with the exception of B95-8 (data not shown). No reactivity of this MAb was observed immediately following infection (i.e., within 2 h), eliminating the possibility of false-positive results originating from the detection of antigens present in the inoculum. Late HHV-6 antigen expression was measured with MAb HAR1-5, which reacts with a glycoprotein of 110 and 60 kDa. Flow cytometric analyses performed on infected cell lines showed reactivity against all of the cell types, except B95-8. As shown in Fig. 1 Effect of HHV-6 on Zebra antigen expression. Having determined that HHV-6 can efficiently infect cells of the B lineage carrying the EBV genome, we studied the influence of HHV-6 infection on the expression of EBV lytic-cycle antigens. Figure  4 represents expression of the Zebra antigen following infection of various cell lines with HHV-6. Striking increases in Zebra antigen expression in the Raji (10-fold) and Akata (5-fold) cell lines were observed following HHV-6 infection. Zebra antigen expression in mock-treated Raji and Akata cells was < 1%. Following infection of these cells with HHV-6, the percentages of cells expressing the Zebra antigen were 6% (Raji) and 4% (Akata). MAb BZ.1 showed no reactivity on HHV-6-infected EBV-negative cells. A typical CPE was observed following infection of these cell lines with HHV-6 (Fig.  4, inset) . Enlarged, vacuolized cells with the tendency to form syncytia were noted. Infection of P3HR1 cells with upregulated Zebra expression by twofold. Seven percent of mock-treated P3HR1 cells were positive for Zebra, whereas about 15% of P3HR1 cells were positive for the same antigen following HHV-6 infection. B95-8 cells, which were not susceptible to HHV-6 infection, were used as a negative control. As shown in Fig. 4 , treatment of these cells with HHV-6 had no effect on Zebra expression. (Fig. 5A) . Similarly, a two-to fourfold increase in EA-D expression was noted following HHV-6 infection of P3HRI (13%) and Akata (4%) cells compared with mock-treated P3HR1 (7%) and Akata (1%) cells (Fig.  SA) . Analysis of EA-D by Western blotting (Fig. 5B) (Fig. 5C) .
The kinetics of EA-D induction by HHV-6 in P3HR1 and Raji cells was also studied. As shown in Fig. 6 Influence of HHV-6 on expression of EBV late antigens. EBV lytic antigens are expressed in a cascade fashion: first, the immediate-early genes, the early genes, and then the late genes are expressed. This study has thus far focused on the expression of immediate-early and early genes of EBV. To analyze whether HHV-6 can also influence the expression of EBV late genes, we studied the expression of two structural proteins of EBV following infection of B cells with HHV-6. First, as shown in Fig. 7 , HHV-6 upregulated the synthesis of the VCA in the P3HR1 and Akata cell lines. Expression of the VCA in mock-treated P3HRI and Akata cells was evaluated at 6 and 3%, respectively. Following 72 h of infection with HHV-6, the number of VCA-positive cells was increased by two-to threefold. Thirteen percent of HHV-6-infected P3HR1 cells expressed the VCA, while 12% of infected Akata cells were positive for the VCA. The MAb used reacted with the 125-kDa component of the EBV VCA. Raji cells, which are known not to synthesize late antigens, were used as a negative control. The second structural protein of EBV that was studied following infection of B cells with HHV-6 was major envelope glycoprotein gp350. Cell surface expression of EBV gp350 was assessed by flow cytometry with MAbs 2L10 and 72A1. As shown in Table 1 this is due to the difference in sensitivity of the two assays used. Treatment of Akata cells with anti-human IgG or P3HR1 with TPA (positive controls) increased gp350 expression by 5-to 10-fold. Expression of gp350 was also studied with Raji cells. As shown in Table 1 , mock-, HHV-6-, or TPA-treated cells failed to express the gp350 molecule. Effects of infectious and inactivated HHV-6 on Zebra antigen and EA-D synthesis. The results presented above indicate that HHV-6 can activate the full EBV replicative cycle, provided that the cell line is susceptible to HHV-6 infection. To assess whether infectious HHV-6 is required for EBV reactivation, we treated Raji cells with UV-irradiated or heat-inactivated HHV-6 and examined these cells for EBV antigens. As shown in Table 2 , HHV-6-infected Raji cells expressed about 10 times more Zebra antigen and EA-D than did mock-infected cells. Cells treated with UV-irradiated or heat-inactivated HHV-6 showed no detectable HHV-6 antigen, indicating that the treatments were effective. Similarly, when these cells were treated with noninfectious HHV-6, no increase in Zebra antigen or EA-D was observed (since less than 1% of cells expressed these antigens), indicating the need for infectious HHV-6 for reactivation of EBV replication.
Both EBV and HHV-6 glycoproteins can be found in the same cells. Next, we had to determine whether EBV reactivation is a direct consequence of HHV-6 infection. To answer this question, we performed dual-color membrane immunofluorescence on HHV-6-and mock-infected P3HR-1 cells and tested for the presence of both EBV gp350 and HHV-6 gp56/20 in the same cell(s). MAbs 2L10 (anti-gp350) and P11E8 (anti-gp56/20) were directly labelled with FITC and RITC, respectively, as described in Materials and Methods. As shown in Fig. 8 (12, 13) .
The EBV lytic cycle has been most extensively studied by reactivating latently infected B cells with various chemical inducers (30, 43, 72 (5, 56) . Raji is an EBV genome-positive Burkitt tumor cell line that has at least two viral genomic deletions, limiting the expression of EBV to EAs (23, 52) . However, expression of late genes can be induced through complementation after superinfection with the P3HR1 virus (5, 54) . The need to identify other agents that trigger EBV replication is of medical importance, especially in regard to the mechanism and etiology of EBV-associated disease processes. In the present study, we provided evidence indicating that HHV-6 induces EBV to reactivate in B-cell lines.
HHV-6 infection of B-cell lines, namely, Raji, Akata, and P3HR1, resulted in an increase of Zebra protein synthesis. Zebra is a 38-kDa nuclear protein, encoded by the BZLF1 genomic segment, whose function is to transactivate downstream early EBV genes by binding to consensus DNA sequences (9, 11, 34, 61) . This immediate-early EBV protein is known to be crucial for the switch from latency to the lytic cycle (11, 34, 61 immunofluorescence, no evidence of HHV-6 infection was recorded. A likely explanation for the inability of HHV-6 to infect B95-8 cells is that HHV-6 has a narrow host range and the B95-8 cell line is derived from marmoset peripheral blood lymphocytes infected with EBV from a patient with infectious mononucleosis. This corroborates the results of Lusso et al. (46) , which showed that of six monkey species tested, HHV-6 was able to infect only peripheral blood leukocytes derived from chimpanzee. Included in the study were peripheral blood leukocytes from a common marmoset, which were found to be refractory to HHV-6 infection (46) . The lack of a cellular receptor for HHV-6 on the surface of B95-8 cells is one hypothesis that explains the above-described results. Susceptibility of B cells to HHV-6 infection seems, therefore, to be a requirement for the observed EBV antigen induction.
Similar to induction of the Zebra antigen, other early EBV antigens were also upregulated by infection of HHV-6. Infection of B cells led to an increase in the D component, which consists of two proteins encoded by the BMRF1 (-50 kDa) and BMLF1 (--60 kDa) genomic segments (65, 66) . The EA-D proteins are involved in the transactivation of other EBV genes (41, 65, 66) . Furthermore, HHV-6 infection of B cells resulted in upregulation of the 85-kDa protein of the R component, encoded by the BORF2 gene segment of EBV (18, 44) . The 85-kDa protein of EBV shares extensive sequence homology with the ribonucleotide reductase of herpes simplex virus (18) .
The EA-D and EA-R components can be distinguished on the basis of their differential solubilities in methanol (26) . Subsequent to the synthesis of the EAs is the replication of viral DNA, followed by synthesis of structural proteins, also termed late antigens. These proteins are the last to be synthesized prior to synthesis of late EBV antigens in at least two cell lines. Both the VCA and envelope glycoprotein gp350 showed increased expression after HHV-6 infection in the P3HR1 and Akata cell lines, suggesting that HHV-6 can induce the full EBV replicative cycle. In addition, results obtained following dual-color membrane immunofluorescence staining of HHV-6-infected P3HR1 cells indicate that the B cells that replicate HHV-6 are also those that replicate EBV. Infection of Raji cells with HHV-6 resulted in no detectable gp350 or VCA suggesting, among other things, a lack of functional or genomic complementation between these two viruses. This could well be related to the limited degree of homology between EBV and HHV-6 DNAs (39).
Inducers of EBV replication, such as HHV-6, are of importance when considering serious complications associated with recurrent EBV infections. In patients afflicted with genetic (X linked) or acquired (HIV or immunosuppressive therapy) immunodeficiencies, EBV infection and reactivation can lead to grave and sometime fatal outcomes (36, 53, 70, 71) . Because of reduced or nonfunctional immunity, B-cell proliferation (possibly through immortalization of these cells by reactivated EBV) is observed. EBV-associated polymorphic B-cell lymphoma is one possible outcome of such lymphoproliferation (27) . HHV-6 has also been linked to lymphoproliferative disease and therefore may also contribute to lymphomagenesis (32, 37) . Since the majority of the population is seropositive for HHV-6, reactivation of HHV-6 in immunocompromised patients may further accentuate EBV replication and thereby contribute to the lymphoproliferation observed.
On the basis of immunoglobulin gene rearrangement studies or EBV terminus analysis, the tumors found in patients are, at least initially, polyclonal in origin (7, 10) . This suggests that neoplastic cells arise from the initial infection of many different B lymphocytes by EBV. With time, the lymphoma evolved to an oligo-or monoclonal state (7, 10) . By inducing EBV, HHV-6 may, therefore, contribute to an increase in the B-cell pool infected with EBV, thereby increasing the chances of developing an EBV-related lymphoma. Taken together, the present study illustrates the interactions between two viruses, both belonging to the same family, which can infect B lymphocytes. We have demonstrated that infection of EBV genomepositive cells by HHV-6 leads to reactivation of EBV. Further studies are needed to better understand how viral cooperation may contribute to disease processes.
